CURRENT CONCEPTS IN RADIOTHERAPY FOR BENIGN DISORDERS

CurrentConceptsinRadiotherapyforBenignDisorders1-0-25kapak

Pterygium and Graves Ophtalmopathy

EBRU ATASEVER AKKAŞa
aUniversity Of Health Sciences Gülhane Faculty of Medicine, Department of Radiation Oncology, Ankara, Türkiye

Atasever Akkaş E. Pterygium and graves ophtalmopathy. In: Uysal B, Gamsız H, eds. Current Concepts in Radiotherapy for Benign Disorders. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.1-5.

ABSTRACT
Many benign diseases can cause significant symptoms or dysfunction. Some of these diseases can be successfully treated with radiotherapy (RT). When benign diseases have a lasting impact on the quality of life by causing pain or other severe symptoms, there may be an indication for RT if other treatment options are not available, have failed or are causing more side effects. In general, however, RT is rarely the first choice in the treatment of benign diseases. Therefore the process of informed consent should be particularly thorough. The risk of late side effect outcomes, such as induction of secondary malignancies, including hematologic malignancies and solid tumors require particular attention. With available clinical data, treatment techniques, and an understanding of cost and potential harm, the goal should be to achieve long-term control of the disease while minimizing unnecessary treatment and potential side effect risks. Among these benign diseases, pterygium and Graves’ ophthalmopathy are the most important benign diseases of the orbit or eye treated with RT.

Keywords: Pterygium; Graves ophthalmopathy; radiotherapy

Referanslar

  1. Rule WG, McGee LA, Seegenschmiedt MH, Halyard MY. Benign Diseases. In: Tepper JE, Foote RL, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Philadelphia, DC: Elsevier; 2021. p.1386-97.
  2. Ringland AJ. A pterygium map. Acta Ophthalmol. 1954;3:1631-42.
  3. Wilder RB, Buatti JM, Kittelson JM, Shimm DS, Harari PM, Rogoff EE, et al. Pterygium treated with excision and postoperative beta irradiation. int J Radiat Oncol Biol Phys. 1992;23(3):533-7. [Crossref]  [PubMed]
  4. Monteiro-Grillo I, Gaspar L, Monteiro-Grillo M, Pires F, Ribeiro da Silva JM. Postoperative irradiation of primary or recurrent pterygium: results and sequelae. Int J Radiat Oncol Biol Phys. 2000;48(3):865-9. [Crossref]  [PubMed]
  5. Luthra R, Nemesure BB, Wu SY, Xie SH, Leske MC; Barbados eye Studies group. Frequency and risk factors for pterygium in the Barbados eye Study. Arch Ophthalmol. 2001;119(12):1827-32. [Crossref]  [PubMed]
  6. Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem. 1996;98(2):195-201. [Crossref]  [PubMed]
  7. Nakagami T, Watanabe I, Murakami A, Okisaka S, Ebihara N. Expression of stem cell factor in pterygium. Jpn J Ophthalmol. 2000;44(3):193-7. [Crossref]  [PubMed]
  8. Wong YW, Chew J, Yang H, Tan DT, Beuerman R. Expression of insulin-like growth factor binding protein-3 in pterygium tissue. Br J Ophthalmol. 2006;90(6):769-72. [Crossref]  [PubMed]  [PMC]
  9. Eng TY, Boersma MK, Fuller CD, Luh JY, Siddiqi A, Wang S, et al. the role of radiation therapy in benign diseases. Hematol Oncol Clin north Am. 2006;20(2):523-57. [Crossref]  [PubMed]
  10. Pollom E, Beadle BM, Singh AD, Suh JH. Ocular, Orbital and Optic Nerve Tumors. In: Tepper JE, Foote RL, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Philadelphia, DC: Elsevier; 2021. p.570-90.
  11. Chen PP, Ariyasu RG, Kaza V, LaBree LD, McDonnell PJ. A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. Am J Ophthalmol. 1995;120(2):151-60. [Crossref]  [PubMed]
  12. Pajic B, Pallas A, Aebersold D, Gruber G, Greiner RH. Prospective study on exclusive, nonsurgical strontium-/yttrium-90 irradiation of pterygia. Strahlenther Onkol. 2004;180(8):510-6. [Crossref]  [PubMed]
  13. Pajic B, Greiner RH. Long term results of non-surgical, exclusive strontium/yttrium-90 beta-irradiation of pterygia. Radiother Oncol. 2005;74(1):25-9. [Crossref]  [PubMed]
  14. Vastardis I, Pajic B, Greiner RH, Pajic-eggspuehler B, Aebersold DM. Prospective study of exclusive strontium-/yttrium-90 beta-irradiation of primary and recurrent pterygia with no prior surgical excision. Clinical outcome of long-term follow-up. Strahlenther Onkol. 2009;185(12):808-14. [Crossref]  [PubMed]
  15. Paryani SB, Scott WP, Wells JW Jr, Johnson DW, Chobe RJ, Kuruvilla A, et al. Management of pterygium with surgery and radiation therapy. The North Florida Pterygium Study Group. Int J Radiat Oncol Biol Phys. 1994;28(1):101-3. [Crossref]  [PubMed]
  16. Vandenbrenk H. Results of prophylactic postoperative irradiation in 1,300 cases of pterygium. American Journal of Roentgenology.1968;103(4):723-33. [Crossref]
  17. Jürgenliemk-Schulz IM, Hartman LJ, Roesink JM, Tersteeg RJ, van Der Tweel I, Kal HB, et al. Prevention of pterygium recurrence by postoperative singledose beta-irradiation: a prospective randomized clinical double-blind trial. Int J radiat Oncol Biol Phys. 2004;59(4):1138-47. [Crossref]  [PubMed]
  18. Viani GA, De Fendi LI, Fonseca EC, Stefano EJ. Low or high fractionation dose β-radiotherapy for pterygium? A randomized clinical trial. int J Radiat Oncol Biol Phys. 2012;82(2):e181-5. [Crossref]  [PubMed]
  19. Rigendinger F, Aebersold DM, Cvejic Z, Pajic B. Changes of Corneal Biomechanical Properties upon exclusive ytt-/Sr-90 Irradiation of Pterygium. Sensors (Basel). 2021;21(3):975. [Crossref]  [PubMed]  [PMC]
  20. Aswad MI, Baum J. Optimal time for postoperative irradiation of pterygia. Ophthalmology. 1987;94(11):1450-1. [Crossref]  [PubMed]
  21. MacKenzie FD, Hirst LW, Kynaston B, Bain C. Recurrence rate and complications after beta irradiation for pterygia. Ophthalmology. 1991;98(12):1776-80; discussion 1781. [Crossref]  [PubMed]
  22. Bahn RS. Clinical review 157: Pathophysiology of graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab. 2003;88(5):1939-46. [Crossref]  [PubMed]
  23. Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for graves' orbitopathy. J Clin Endocrinol Metab. 2012;97(11):3857-65. [Crossref]  [PubMed]
  24. Mourits MP, van Kempen-Harteveld ML, García MB, Koppeschaar HP, Tick L, Terwee CB. radiotherapy for Graves' orbitopathy: randomised placebocontrolled study. Lancet. 2000;355(9214):1505-9. [Crossref]  [PubMed]
  25. Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' Ophthalmopathy. J Clin Endocrinol Metab. 2004;89(1):15-20. [Crossref]  [PubMed]
  26. Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL,et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology. 2001;108(9):1523-34. [Crossref]  [PubMed]
  27. Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet. 1993;342(8877):949-54. [Crossref]  [PubMed]
  28. Bartalena L, Marcocci C, Chiovato L, Laddaga M, Lepri G, Andreani D, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab. 1983;56(6):1139-44. [Crossref]  [PubMed]
  29. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest. 1991;14(10):853-60. [Crossref]  [PubMed]
  30. Rajendram R, taylor PN, Wilson VJ, Harris N, Morris OC, Tomlinson M, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(4):299-309. [Crossref]  [PubMed]
  31. Godfrey KJ, Kazim M. Radiotherapy for Active thyroid eye Disease. Ophthalmic Plast Reconstr Surg. 2018;34(4S Suppl 1):S98-S104. [Crossref]  [PubMed]
  32. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'unto e, rocchi r, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001;86(8):3562-7. [Crossref]  [PubMed]
  33. Kim JW, Han SH, Son BJ, Rim TH, Keum KC, Yoon JS. Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254(5):991-8. [Crossref]  [PubMed]
  34. Oeverhaus M, Witteler T, Lax H, Esser J, Führer D, Eckstein A. Combination therapy of intravenous Steroids and Orbital irradiation is more effective than intravenous Steroids Alone in Patients with graves' Orbitopathy. Horm Metab Res. 2017;49(10):739-47. [Crossref]  [PubMed]
  35. Kahaly GJ, Rösler HP, Pitz S, Hommel G. Low-versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab. 2000;85(1):102-8. [Crossref]  [PubMed]
  36. Arenas M, Sabater S, Jiménez PL, rovirosa À, Biete A, Linares V, et al. Radiotherapy for Graves' disease. The possible role of low-dose radiotherapy. Rep Pract Oncol Radiother. 2016;21(3):213-8. [Crossref]  [PubMed]  [PMC]
  37. Marcocci C, Bartalena L, Rocchi R, Marinò M, Menconi F, Morabito e, et al. Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab. 2003;88(8):3561-6. [Crossref]  [PubMed]
  38. Wakelkamp IM, Tan H, Saeed P, Schlingemann RO, Verbraak FD, Blank le, et al. Orbital irradiation for Graves' ophthalmopathy: is it safe? A long-term follow-up study. Ophthalmology. 2004;111(8):1557-62. [Crossref]  [PubMed]